Status:
UNKNOWN
Ticagrelor and Endothelial Function
Lead Sponsor:
Hotel Dieu de France Hospital
Conditions:
Antiplatelet Agents; Endothelial Function; Pleotropic Effects
Eligibility:
All Genders
21-75 years
Phase:
PHASE4
Brief Summary
To evaluate the effect of ticagrelor on endothelial function as measured by flow mediated dilation of the brachial artery. This will be compared to prasugrel.
Detailed Description
Objective: Demonstrate an improvement in endothelial function with ticagrelor Introduction and hypothesis: Ticagrelor and prasugrel are 2 new platelet antagonists. Both are superior to clopidogrel ...
Eligibility Criteria
Inclusion
- \- Prior MI \> 1 year old
- Prior PCI \> 1 year old
- Prior CABG \> 3 months old
- Known lesion causing more than 50% stenosis on coronary angiography
Exclusion
- Acute coronary syndrome within the last 6 months
- Any history of bleeding
- Age \> 75 years
- Weight \< 65 kg
- Prior stroke or TIA
- Platelet count \< 100,000
- Hemoglobin \< 11 mg/dL
- Patients who have received ticagrelor, prasugrel or clopidogrel in the 3 months that preceded randomization
- Patients who are taking anti-thrombotic therapy
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02261922
Start Date
October 1 2014
End Date
November 1 2015
Last Update
October 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hotel Dieu de France Hospital
El Achrafiyé, Beyrouth, Lebanon, Beirut